valsartan / hydrochlorothiazide teva 80 mg/12.5 mg film-coated tablets
teva pharma b.v. - valsartan; hydrochlorothiazide - film-coated tablet - 80 mg/12.5 milligram(s) - angiotensin ii antagonists and diuretics; valsartan and diuretics
valsartan / hydrochlorothiazide teva 160 mg/25 mg film-coated tablets
teva pharma b.v. - valsartan; hydrochlorothiazide - film-coated tablet - 160 mg/25 milligram(s) - angiotensin ii antagonists and diuretics; valsartan and diuretics
valsartan/hydrochlorothiazide teva 160 mg/12.5 mg film-coated tablets
teva pharma b.v. - valsartan; hydrochlorothiazide - film-coated tablet - 160 mg /12.5 milligram(s) - angiotensin ii antagonists and diuretics; valsartan and diuretics
valsartan and hydrochlorothiazide tablet, film coated
northwind pharmaceuticals - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - valsartan 160 mg - valsartan and hydrochlorothiazide tablets, usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the arb class to which valsartan principally belongs. there are no controlled trials demonstrating risk reduction with valsartan and hydrochlorothiazide tablets, usp. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education p
valsartan tablet, film coated
northwind pharmaceuticals - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - valsartan 160 mg - 1.1 hypertension valsartan tablets, usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs. there are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets, usp. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee
apo-valsartan valsartan 320 mg tablet blister pack
apotex pty ltd - valsartan -
apo-valsartan valsartan 160 mg tablet blister pack
apotex pty ltd - valsartan -
apo-valsartan valsartan 80 mg tablet blister pack
apotex pty ltd - valsartan -
apo-valsartan valsartan 40 mg tablet blister pack
apotex pty ltd - valsartan -
valsartan teva 80 mg film-coated tablets
teva pharma b.v. - valsartan - film-coated tablet - 80 milligram(s) - angiotensin ii antagonists, plain; valsartan